Decoding Treatment Response in Hepatocellular Carcinoma: The Era of Radiomics and Radiogenomics
Zongding Wang1,2, Wenjie Gan3, Jianping Gong3
1Department of Hepatobiliary Surgery, Chongqing Dianjiang People's Hospital, Chongqing, 408300, People's Republic of China.
Abstract:
Hepatocellular carcinoma (HCC) immunotherapy is significantly constrained by a low objective response rate (~30%) and the lack of universally applicable predictive biomarkers. Radiomics, a non-invasive technique that extracts high-throughput hidden features from medical images, offers innovative solutions for patient selection, treatment response assessment, and prognosis prediction. This review systematically summarizes the application scenarios, feature extraction, and model construction of multimodal imaging data in HCC immunotherapy. It highlights advances in radiomics for predicting treatment response and evaluating the tumor immune microenvironment (TIME) and underlying molecular signatures. It also analyzes key challenges, including limited sample sizes and poor model generalization, and outlines future directions such as multicenter standardized studies and multi-omics integration. The goal is to inform the clinical translation of radiomics for precision management of HCC immunotherapy.
Insights
Radiomics analysis of medical images can improve hepatocellular carcinoma (HCC) immunotherapy by predicting treatment response and patient selection. This approach aids in overcoming current limitations and advancing precision medicine for HCC.
Area of Science:
- Oncology
- Radiology
- Immunotherapy
Background:
- Hepatocellular carcinoma (HCC) immunotherapy faces challenges with low response rates and limited predictive biomarkers.
- Radiomics offers a non-invasive method to extract detailed imaging features for improved patient management.
Purpose of the Study:
- To systematically review radiomics applications in HCC immunotherapy.
- To highlight radiomics' role in predicting treatment response, assessing the tumor immune microenvironment (TIME), and identifying molecular signatures.
- To discuss challenges and future directions for clinical translation.
Main Methods:
- Systematic review of multimodal imaging data in HCC immunotherapy.
- Analysis of radiomics feature extraction and model construction techniques.
- Evaluation of radiomics for predicting treatment outcomes and TIME characteristics.
Main Results:
- Radiomics shows promise in predicting HCC immunotherapy response and characterizing the TIME.
- Multimodal imaging data and advanced feature extraction enhance predictive capabilities.
- Key challenges include small sample sizes and limited model generalizability.
Conclusions:
- Radiomics is a valuable tool for enhancing HCC immunotherapy precision.
- Standardized multicenter studies and multi-omics integration are crucial for future development.
- Clinical translation of radiomics can optimize patient selection and treatment strategies for HCC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers
Pharmacogenomics: Identification of New Drug Targets


